Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Troxacitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.60 |
| ▸ | ALB | P02768 | 3/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.60 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | POLG | P54098 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troxacitabine SCHEMBL1026150 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL18548 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL1026148 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL6424800 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL1844439 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL30317744 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL22285889 | 0.99 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL17542009 | 0.95 | LMNA (0.56) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL7560355 | 0.89 | POLG (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL31347648 | 0.88 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504778-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH A CYTIDINE ANALOGUE OR DEOXYCYTIDINE ANALOGUE | UCB Biopharma SRL (BE) | 2025-02-12 | — | — | EP | disclosed |
| CN-119343372-A | Combinations of Gremlin-1 antagonists with cytidine analogs or deoxycytidine analogs | UCB生物制药有限责任公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2023194584-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH A CYTIDINE ANALOGUE OR DEOXYCYTIDINE ANALOGUE | UCB Biopharma SRL (BE) | 2023-10-12 | — | — | WO | disclosed |
| CN-116768843-A | Preparation method of glycolaldehyde dimer | 中国科学院合肥物质科学研究院 | 2023-09-19 | — | — | CN | disclosed |
| US-11731959-B2 | Troxacitabine synthesis and crystal form thereof | BEIJING HEBABIZ BIOTECHNOLOGY CO., INC. (CN) | 2023-08-22 | — | — | US | disclosed |
| US-11731959-B2 | Troxacitabine synthesis and crystal form thereof | BEIJING HEBABIZ BIOTECHNOLOGY CO., INC. (CN) | 2023-08-22 | — | — | US | disclosed |
| US-20200247787-A1 | TROXACITABINE SYNTHESIS AND CRYSTAL FORM THEREOF | BEIJING HEBABIZ BIOTECHNOLOGY CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| EP-3572410-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | Medivir Aktiebolag (SE) | 2019-11-27 | — | — | EP | disclosed |
| US-20130011392-A1 | METHOD FOR ASSESSING THE ABILITY OF A PATIENT TO RESPOND TO OR BE SAFELY TREATED BY A NUCLEOSIDE ANALOG BASED-CHEMOTHERAPY | ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE (FR) | 2013-01-10 | — | — | US | disclosed |
| WO-2011061278-A1 | A METHOD FOR ASSESSING THE ABILITY OF A PATIENT TO RESPOND TO OR BE SAFELY TREATED BY A NUCLEOSIDE ANALOG BASED-CHEMOTHERAPY | UNIVERSITE DE LA MEDITERRANEE (FR) | 2011-05-26 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731959-B2 | Troxacitabine synthesis and crystal form thereof | TBXAS1, TTPA, TBCB | POLA1 2452/4885LMNA 2641/4885PDE3A 3102/4885 |
| US-20200247787-A1 | TROXACITABINE SYNTHESIS AND CRYSTAL FORM THEREOF | TBXAS1, TTPA, TBCB | POLA1 2452/4885LMNA 2641/4885PDE3A 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.